US4843071A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for treating obesity, drug abuse, and narcolepsy
Assignee: SEROTONIN INDUSTRIES OF CHARLESTON A LP
•
Filing: 1986-12-05
•
Granted: 1989-06-27
•
Expires: 2006-12-05
Abstract
Abstract Compositions and methods are disclosed for the treatment of obesity, depression, drug abuse, and narcolepsy. The compositions comprise a norepinephrine precursor such as L-tyrosine or L-phenylalanine in combination with a norepinephrine re-uptake inhibitor such as desipramine. In another embodiment of the invention, the compositions further comprise enzymatic cofactors for the biosynthesis of norepinephrine.
Inventors
- 👤 Mark Hohenwarter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 20:27
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/55; A61P; A61P25/00; A61P25/24; A61P25/26; A61P25/30; A61P3/00; A61P3/04; Y; Y10; Y10S; Y10S424/00; Y10S424/15
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
26 words
A composition useful for the treatment of obesity, drug abuse and narcolepsy comprising effective amount of: a. a norepinephrine precursor; and b. a norepinephrine re-uptake inhibitor.
Claim 2
Dependent Claim
26 words
A composition useful for the treatment of obesity, drug abuse and narcolepsy comprising effective amount of: a. a norepinephrine precursor; and b. a norepinephrine re-uptake inhibitor.
Claim 3
Dependent Claim
21 words
The composition of claim 1 further comprising an effective amount of one or more enzymatic cofactors for the biosynthesis of norepinephrine.
Claim 4
Dependent Claim
12 words
The composition of claims 1 or 2 and a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
23 words
The composition of claim 3 in the form of a liquid, a suspension, a tablet, a dragee, an injectable solution, or a suppository.
Claim 6
Dependent Claim
33 words
The composition of claim 2 wherein the enzymatic cofactors include at least one of pyridoxine, ascorbic acid, or the pharmaceutically acceptable salts thereof in an amount, effective to enzymatically cofactor biosynthesis of norepinephrine.
Claim 7
Dependent Claim
25 words
The composition of claim 1 wherein the norepinephrine precursor is selected from the group consisting of L-tyrosine and L-phenylalanine, or the pharmaceutically acceptable salts thereof.
Claim 8
Dependent Claim
11 words
The composition of claim 6 wherein the norepinephrine precursor is L-tyrosine.
Claim 9
Dependent Claim
30 words
The composition of claim 1 wherein the norephinephrine re-uptake inhibitor is selected from the group consisting of desipramine, imipramine, amoxapine, nortriptyline, protriptyline, and maprotiline, or the pharmaceutically acceptable salts thereof.
Claim 10
Dependent Claim
12 words
The composition of claim 8 wherein the norepinephrine re-uptake inhibitor is desipramine.
Claim 11
Dependent Claim
50 words
The composition of claim 1 comprising, per part by weight of the norepinephrine re-uptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine re-uptake inhibitor, 0.5-500 parts by weight of said norepinephrine precursor or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine precursor.
Claim 12
Dependent Claim
89 words
The composition of claim 5 comprising, per part by weight of the norepinephrine re-uptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine re-uptake inhibitor, 0.5-500 parts by weight of said norepinephrine precursor, or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine precursor, 0.05-4 parts by weight of pyridoxine or an equivalent amount of a pharmaceutically acceptable salt of pyridoxine, and 0.4-20 parts by weight of said ascorbic acid or an equivalent amount of a pharmaceutically acceptable salt of said ascorbic acid.
Claim 13
Dependent Claim
23 words
The composition of claim 1 comprising, per unit dose, 125-2000 mg of said norepinephrine precursor and 10-75 mg of said norepinephrine re-uptake inhibitor.
Claim 14
Dependent Claim
21 words
The composition of claim 7 comprising, per unit dose, 125-2000 mg of L-tyrosine and 10-75 mg of said norepinephrine re-uptake inhibitor.
Claim 15
Dependent Claim
20 words
The composition of claim 8 comprising, per unit dose, 10-75 mg of desipramine and 125-2000 mg of a norepinephrine precursor.
Claim 16
Dependent Claim
32 words
The composition of claim 5 comprising, per unit dose, 125-2000 mg of said norepinephrine precursor, 10-75 mg of said norepinephrine re-uptake inhibitor, 10-100 mg of pyridoxine, and 50-500 mg of ascorbic acid.
Claim 17
Dependent Claim
20 words
The composition of claim 15 wherein the said norepinephrine precursor is L-tyrosine and the said norepinephrine re-uptake inhibitor is desipramine.
Claim 18
Independent Claim
33 words
A method for treating obesity, drug abuse, or narcolepsy in an animal comprising administering to said animal a composition comprising effective amounts of: a. a norepinephrine precursor; and b. a norepinephrine re-uptake inhibitor.
Claim 19
Independent Claim
33 words
A method for treating obesity, drug abuse, or narcolepsy in an animal comprising administering to said animal a composition comprising effective amounts of: a. a norepinephrine precursor; and b. a norepinephrine re-uptake inhibitor.
Claim 20
Dependent Claim
20 words
The method of claim 17 wherein said composition further comprises one or more enzymatic cofactors for the biosynthesis of norepinephrine
Claim 21
Dependent Claim
33 words
The method of claim 18 wherein said enzymatic cofactors include at least one of pyridoxine, ascorbic acid or the pharmaceutically acceptable salts thereof in an amount, effective to enzymatically cofactor biosynthesis of norepinephrine.
Claim 22
Dependent Claim
11 words
The method of claim 17 wherein said animal is a human.
Claim 23
Independent Claim
63 words
The method of claims 17, 18, or 19 wherein said norepinephrine precursor is selected from the group of consisting of L-phenylalanine, L-tyrosine, and the pharmaceutically acceptable salts of L-phenylalanine and L-tyrosine, and said norepinephrine re-uptake inhibitor is selected from the group consisting of desipramine, imipramine, amoxapine, nortriptyline, protriptyline, and maprotiline, and the pharmaceutically acceptable salts of desipramine, imipramine, amoxapine, nortriptyline, protriptyline, and maprotiline.
Claim 24
Dependent Claim
50 words
The method of claim 17 wherein said composition comprises per part by weight of said norepinephrine re-uptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine re-uptake inhibitor, 0.5-500 parts by weight of the norepinephrine precursor or an equivalent amount of the pharmaceutically acceptable salt thereof.
Claim 25
Dependent Claim
79 words
The method of claim 19 wherein said composition comprises, per part by weight of said norepinephrine re-uptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine re-uptake inhibitor, 0.5-500 parts by weight of said norepinephrine precursor, 0.05-4 parts by weight of pyridoxine or an equivalent amount of a pharmaceutically acceptable salt of pyridoxine, and 0.4-20 parts by weight of said ascorbic acid or an equivalent amount of a pharmaceutically acceptable salt of said ascorbic acid.
Claim 26
Independent Claim
101 words
The method of claim or 19 wherein said composition is administered to said animal one to eight times per day, each unit dose containing 125-2000 mg of said norepinephrine precursor or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine precursor, 10-75 mg of said norepinephrine re-uptake inhibitor or an equivalent amount of the pharmaceutically acceptable salt of said norepinephrine re-uptake inhibitor, 10-100 mg of said pyridoxine or an equivalent amount of the pharmaceutically acceptable salt of said pyridoxine, and 50-500 mg. of said ascorbic acid or an equivalent amount of the pharmaceutically acceptable salt of said ascorbic acid.
Claim 27
Dependent Claim
23 words
The method of claim 17, wherein said composition comprises, per unit dose, 1 gm L-tyrosine and 25 mg desipramine administered four times daily.
Claim 28
Dependent Claim
26 words
The method of claim 19, wherein said composition comprises, per unit dose, 1 gm L-tyrosine, 25 mg desipramine, 50 mg pyridoxine and 250 mg ascorbic acid.
Claim 29
Dependent Claim
14 words
The method of claim 17, wherein said composition further comprises a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-06-26 | 1992-12-26 | 1993-06-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-06-26 | 1996-12-26 | 1997-06-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-06-26 | 2000-12-26 | 2001-06-27 | $7700.00 | Window Closed / Lapsed |